[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Waseem Bihaqi et al., 2012 - Google Patents

Do epigenetic pathways initiate late onset Alzheimer disease (LOAD): towards a new paradigm

Waseem Bihaqi et al., 2012

View PDF
Document ID
5029191868858290390
Author
Waseem Bihaqi S
Schumacher A
Maloney B
K. Lahiri D
H. Zawia N
Publication year
Publication venue
Current Alzheimer Research

External Links

Snippet

Late onset Alzheimer's disease (LOAD) is a non-familial, progressive neurodegenerative disease and the most prominent form of dementia in the elderly. Accumulating evidence suggests that LOAD not only results from the combined effects of variation in a number of …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Similar Documents

Publication Publication Date Title
Waseem Bihaqi et al. Do epigenetic pathways initiate late onset Alzheimer disease (LOAD): towards a new paradigm
Jiang et al. Epigenetic modifications in stress response genes associated with childhood trauma
Qazi et al. Epigenetics in Alzheimer’s disease: perspective of DNA methylation
Mann et al. RNA binding antagonizes neurotoxic phase transitions of TDP-43
Landgrave-Gómez et al. Epigenetic mechanisms in neurological and neurodegenerative diseases
Sharma et al. Alzheimer’s disorder: epigenetic connection and associated risk factors
Wang et al. Epigenetic mechanisms in Alzheimer's disease: implications for pathogenesis and therapy
Groen et al. UBA1: at the crossroads of ubiquitin homeostasis and neurodegeneration
Wang et al. Formaldehyde, epigenetics, and Alzheimer’s disease
Wolfe The role of tau in neurodegenerative diseases and its potential as a therapeutic target
Kwok Role of epigenetics in Alzheimer’s and Parkinson’s disease
Gräff et al. Epigenetic dysregulation in cognitive disorders
Robberecht et al. The changing scene of amyotrophic lateral sclerosis
Gomez‐Pinilla et al. Exercise impacts brain‐derived neurotrophic factor plasticity by engaging mechanisms of epigenetic regulation
Wu et al. The environment, epigenetics and amyloidogenesis
Tan et al. Angelman syndrome: current and emerging therapies in 2016
Mantha et al. A short review on the implications of base excision repair pathway for neurons: relevance to neurodegenerative diseases
Narayan et al. Pharmacology of epigenetics in brain disorders
Huang et al. SNCA gene, but not MAPT, influences onset age of Parkinson’s disease in Chinese and Australians
Mather et al. The role of epigenetics in cognitive ageing
Song et al. Epigenetic modification in Parkinson’s disease
Mir et al. Neuroepigenetics of ageing and neurodegeneration-associated dementia: an updated review
Castillo-Ordoñez et al. Genetic and epigenetic targets of natural dietary compounds as anti-Alzheimer’s agents
Blasiak et al. Potential of epigenetic mechanisms in AMD pathology
Liang Cross talk between aluminum and genetic susceptibility and epigenetic modification in Alzheimer’s disease